Search
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805]. … The ophthalmic solution was approved in July, 2016 under the trade name Xiidra.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2C9 InhibitorsGalsulfase
go.drugbank.com/drugs/DB01279ApprovedInvestigationalPost-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family … Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD.
Synonyms: N-acetylgalactosamine-4-sulfatase, recombinant human, Arylsulfatase B galsulfaseProducts: NAGLAZYME®Glutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. … It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Synonyms: N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine, 5-L-Glutamyl-L-cysteinylglycineMixtures: VitaHealth L-Glutathione Plus, Essential Pro ALPHA-G Q10 CapsuleLutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate … It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsProducts: 1 PluvictoPrimidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.
Categories: combinations of barbiturates, Cytochrome P-450 SubstratesSynonyms: 5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione, 2-deoxyphenobarbitalCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalFood and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.
Categories: Carbamoyl Phosphate Synthetase 1 Activator, Carbamoyl Phosphate Synthetase 1 ActivatorsSynonyms: N-Carbamyl-L-glutamate, L-N-Carbamoylglutamic acidPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). … It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.
Mixtures: PHESGO® 600MG/600MG, PHESGO® 600MG/600MGCategories: Receptor, ErbB-2, antagonists & inhibitors, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigationalLanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells.
Categories: Drugs Used in Hereditary AngioedemaProducts: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETGallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigationalprostate cancer or in patients who may have recurrent prostate cancer. … [L43542] In December of the same year, the drug was fully authorized by the EMA.[L44682] In Octer 2022, Ga-68 PSMA-11 was approved by Health Canada for diagnostic use in men with prostate cancer.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsSynonyms: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CCMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 InducersSynonyms: 4'-N-benzoylstaurosporine